Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.

Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K.

J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602. [Epub ahead of print]

PMID:
31584207
2.

Gene targeting in Arabidopsis via an all-in-one strategy that uses a translational enhancer to aid Cas9 expression.

Peng F, Zhang W, Zeng W, Zhu JK, Miki D.

Plant Biotechnol J. 2019 Sep 25. doi: 10.1111/pbi.13265. [Epub ahead of print] No abstract available.

3.

Histone acetylation recruits the SWR1 complex to regulate active DNA demethylation in Arabidopsis.

Nie WF, Lei M, Zhang M, Tang K, Huang H, Zhang C, Miki D, Liu P, Yang Y, Wang X, Zhang H, Lang Z, Liu N, Xu X, Yelagandula R, Zhang H, Wang Z, Chai X, Andreucci A, Yu JQ, Berger F, Lozano-Duran R, Zhu JK.

Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16641-16650. doi: 10.1073/pnas.1906023116. Epub 2019 Jul 30.

PMID:
31363048
4.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K.

J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14.

PMID:
31199224
5.

Characterization of Functional Primary Cilia in Human Induced Pluripotent Stem Cell-Derived Neurons.

Miki D, Kobayashi Y, Okada T, Miyamoto T, Takei N, Sekino Y, Koganezawa N, Shirao T, Saito Y.

Neurochem Res. 2019 Jul;44(7):1736-1744. doi: 10.1007/s11064-019-02806-4. Epub 2019 Apr 29.

PMID:
31037609
6.

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis.

Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, Tanaka J, Chayama K.

Hepatol Commun. 2019 Jan 22;3(3):348-355. doi: 10.1002/hep4.1309. eCollection 2019 Mar.

7.

Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.

Tsushima K, Tsuge M, Hiraga N, Uchida T, Murakami E, Makokha GN, Kurihara M, Nomura M, Hiyama Y, Fujino H, Ono A, Nakahara T, Yamauchi M, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Hayes CN, Chayama K.

J Gastroenterol. 2019 Jul;54(7):650-659. doi: 10.1007/s00535-019-01558-w. Epub 2019 Feb 21.

PMID:
30790056
8.

Shallow magma pre-charge during repeated Plinian eruptions at Sakurajima volcano.

Araya N, Nakamura M, Yasuda A, Okumura S, Sato T, Iguchi M, Miki D, Geshi N.

Sci Rep. 2019 Feb 13;9(1):1979. doi: 10.1038/s41598-019-38494-x.

9.

The genome of broomcorn millet.

Zou C, Li L, Miki D, Li D, Tang Q, Xiao L, Rajput S, Deng P, Peng L, Jia W, Huang R, Zhang M, Sun Y, Hu J, Fu X, Schnable PS, Chang Y, Li F, Zhang H, Feng B, Zhu X, Liu R, Schnable JC, Zhu JK, Zhang H.

Nat Commun. 2019 Jan 25;10(1):436. doi: 10.1038/s41467-019-08409-5.

10.

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2019;23(8):709. doi: 10.3851/IMP3289. No abstract available.

PMID:
30632982
11.

The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.

Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H.

J Med Virol. 2019 Apr;91(4):650-658. doi: 10.1002/jmv.25352. Epub 2018 Nov 19.

PMID:
30381831
12.

Four putative SWI2/SNF2 chromatin remodelers have dual roles in regulating DNA methylation in Arabidopsis.

Yang DL, Zhang G, Wang L, Li J, Xu D, Di C, Tang K, Yang L, Zeng L, Miki D, Duan CG, Zhang H, Zhu JK.

Cell Discov. 2018 Oct 16;4:55. doi: 10.1038/s41421-018-0056-8. eCollection 2018.

13.

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.

Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2019 Mar;54(3):291-296. doi: 10.1007/s00535-018-1520-9. Epub 2018 Oct 17.

PMID:
30334096
14.

DNA demethylase ROS1 negatively regulates the imprinting of DOGL4 and seed dormancy in Arabidopsis thaliana.

Zhu H, Xie W, Xu D, Miki D, Tang K, Huang CF, Zhu JK.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9962-E9970. doi: 10.1073/pnas.1812847115. Epub 2018 Sep 28.

15.

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.

Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N, Shiraishi K, Izaki Y, Makokha GN, Uchida T, Kurihara M, Nomura M, Tsushima K, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Fujita T, Chayama K.

Virology. 2018 Dec;525:48-61. doi: 10.1016/j.virol.2018.08.020. Epub 2018 Sep 18.

PMID:
30240958
16.

Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.

Morio K, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, Fujino H, Nakahara T, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Katamura Y, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group.

J Med Virol. 2018 Dec;90(12):1834-1840. doi: 10.1002/jmv.25267. Epub 2018 Aug 13.

PMID:
30016555
17.

CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients.

Nomura M, Tsuge M, Uchida T, Hiraga N, Kurihara M, Tsushima K, Fujino H, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Zhang Y, Makokha GN, Hayes CN, Tanaka S, Chayama K.

J Viral Hepat. 2018 Dec;25(12):1555-1564. doi: 10.1111/jvh.12970. Epub 2018 Aug 29.

PMID:
29998562
18.

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, Saito Y, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2018 Aug;99(8):1058-1065. doi: 10.1099/jgv.0.001091. Epub 2018 Jun 19.

PMID:
29916799
19.

Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2018;23(8):639-646. doi: 10.3851/IMP3240. Erratum in: Antivir Ther. 2019;23(8):709.

PMID:
29856363
20.

CRISPR/Cas9-mediated gene targeting in Arabidopsis using sequential transformation.

Miki D, Zhang W, Zeng W, Feng Z, Zhu JK.

Nat Commun. 2018 May 17;9(1):1967. doi: 10.1038/s41467-018-04416-0.

21.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.

Teraoka Y, Uchida T, Imamura M, Osawa M, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K; Hiroshima Liver Study Group.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157. doi: 10.1016/j.bbrc.2018.04.005. Epub 2018 Apr 13.

PMID:
29621544
22.

CD105 maintains the thermogenic program of beige adipocytes by regulating Smad2 signaling.

Higa R, Hanada T, Teranishi H, Miki D, Seo K, Hada K, Shiraishi H, Mimata H, Hanada R, Kangawa K, Murai T, Nakao K.

Mol Cell Endocrinol. 2018 Oct 15;474:184-193. doi: 10.1016/j.mce.2018.03.008. Epub 2018 Mar 22.

PMID:
29574003
23.

Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.

Yamauchi M, Urabe Y, Ono A, Miki D, Ochi H, Chayama K.

Int J Cancer. 2018 Apr 1;142(7):1418-1426. doi: 10.1002/ijc.31154. Epub 2017 Nov 29.

24.

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis.

Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio K, Fujino H, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K.

Hepatol Res. 2018 Mar;48(4):264-274. doi: 10.1111/hepr.12996. Epub 2017 Dec 11.

PMID:
29114970
25.

The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients.

Kurihara M, Tsuge M, Murakami E, Mori N, Ohishi W, Uchida T, Fujino H, Nakahara T, Abe-Chayama H, Kawaoka T, Miki D, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Zhang Y, Makokha GN, Hayes CN, Chayama K.

Antivir Ther. 2018;23(3):239-248. doi: 10.3851/IMP3196.

PMID:
28933704
26.

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K.

PLoS One. 2017 Aug 10;12(8):e0182710. doi: 10.1371/journal.pone.0182710. eCollection 2017.

27.

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.

Nakahara T, Hyogo H, Ono A, Nagaoki Y, Kawaoka T, Miki D, Tsuge M, Hiraga N, Hayes CN, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Abe-Chayama H, Furusho H, Shintani T, Kurihara H, Miyauchi M, Takata T, Arihiro K, Chayama K.

J Gastroenterol. 2018 Feb;53(2):269-280. doi: 10.1007/s00535-017-1368-4. Epub 2017 Jul 24.

PMID:
28741270
28.

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00725-17. doi: 10.1128/AAC.00725-17. Print 2017 Sep.

29.

Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.

Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Aikata H, Hayes CN, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K.

J Med Virol. 2017 Nov;89(11):1963-1972. doi: 10.1002/jmv.24885. Epub 2017 Jul 25.

PMID:
28657143
30.

The developmental regulator PKL is required to maintain correct DNA methylation patterns at RNA-directed DNA methylation loci.

Yang R, Zheng Z, Chen Q, Yang L, Huang H, Miki D, Wu W, Zeng L, Liu J, Zhou JX, Ogas J, Zhu JK, He XJ, Zhang H.

Genome Biol. 2017 May 31;18(1):103. doi: 10.1186/s13059-017-1226-y.

31.

Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.

Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K.

J Gastroenterol. 2018 Jan;53(1):161-162. doi: 10.1007/s00535-017-1352-z. No abstract available.

PMID:
28555325
32.

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.

Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K.

J Gastroenterol. 2018 Jan;53(1):107-118. doi: 10.1007/s00535-017-1348-8. Epub 2017 May 4. Erratum in: J Gastroenterol. 2017 May 29;:.

PMID:
28474222
33.

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.

Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T, Chayama K.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00183-17. doi: 10.1128/AAC.00183-17. Print 2017 Jun.

34.

Efficient Generation of diRNAs Requires Components in the Posttranscriptional Gene Silencing Pathway.

Miki D, Zhu P, Zhang W, Mao Y, Feng Z, Huang H, Zhang H, Li Y, Liu R, Zhang H, Qi Y, Zhu JK.

Sci Rep. 2017 Mar 22;7(1):301. doi: 10.1038/s41598-017-00374-7.

35.

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.

Uchida T, Imamura M, Kan H, Hiraga N, Hayes CN, Tsuge M, Abe-Chayama H, Aikata H, Makokha GN, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2017 May;98(5):1040-1047. doi: 10.1099/jgv.0.000726. Epub 2017 May 25.

PMID:
28141486
36.

A pair of transposon-derived proteins function in a histone acetyltransferase complex for active DNA demethylation.

Duan CG, Wang X, Xie S, Pan L, Miki D, Tang K, Hsu CC, Lei M, Zhong Y, Hou YJ, Wang Z, Zhang Z, Mangrauthia SK, Xu H, Zhang H, Dilkes B, Tao WA, Zhu JK.

Cell Res. 2017 Feb;27(2):226-240. doi: 10.1038/cr.2016.147. Epub 2016 Dec 9.

37.

Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.

Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, Ono A, Nakahara T, Abe-Chayama H, Zhang Y, Naswa MG, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Chayama K.

J Gastroenterol. 2016 Nov;51(11):1073-1080. Epub 2016 Mar 4.

PMID:
26943168
38.

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.

Nakamura Y, Imamura M, Kawakami Y, Teraoka Y, Daijo K, Honda F, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Chayama K.

J Med Virol. 2017 Apr;89(4):665-671. doi: 10.1002/jmv.24679. Epub 2016 Oct 24.

PMID:
27602542
39.

SAC3B, a central component of the mRNA export complex TREX-2, is required for prevention of epigenetic gene silencing in Arabidopsis.

Yang Y, La H, Tang K, Miki D, Yang L, Wang B, Duan CG, Nie W, Wang X, Wang S, Pan Y, Tran EJ, An L, Zhang H, Zhu JK.

Nucleic Acids Res. 2017 Jan 9;45(1):181-197. doi: 10.1093/nar/gkw850. Epub 2016 Sep 26.

40.

Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.

Kan H, Imamura M, Uchida T, Hiraga N, Hayes CN, Tsuge M, Abe H, Aikata H, Makokha GN, Chowdhury S, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Infect Dis. 2016 Dec 1;214(11):1687-1694. Epub 2016 Sep 20.

PMID:
27651415
41.

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.

Morio R, Imamura M, Kawakami Y, Morio K, Kobayashi T, Yokoyama S, Kimura Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Nelson Hayes C, Aikata H, Takahashi S, Miki D, Ochi H, Mori N, Takaki S, Tsuji K, Chayama K.

J Gastroenterol. 2017 Apr;52(4):504-511. doi: 10.1007/s00535-016-1255-4. Epub 2016 Sep 8.

PMID:
27631593
42.

Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.

Morio K, Imamura M, Kawakami Y, Morio R, Kobayashi T, Yokoyama S, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Makokha GN, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K.

J Gastroenterol Hepatol. 2017 Mar;32(3):645-650. doi: 10.1111/jgh.13511.

PMID:
27513614
43.

IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.

Mori N, Imamura M, Kawakami Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Takaki S, Tsuji K, Chayama K; Hiroshima Liver Study Group.

Hepatol Res. 2017 Mar;47(3):E5-E13. doi: 10.1111/hepr.12715. Epub 2016 Apr 21.

PMID:
27027531
44.

[Genetic factors in HLA-DP associated with pathology, therapeutic outcome, and prognosis of chronic hepatitis B].

Ochi H, Miki D, Chayama K.

Nihon Rinsho. 2015 Dec;73 Suppl 9:439-42. Japanese. No abstract available.

PMID:
26845974
45.

[HCV persistence and HLA-DQB1].

Miki D, Ochi H, Chayama K.

Nihon Rinsho. 2015 Dec;73 Suppl 9:128-32. Japanese. No abstract available.

PMID:
26845917
46.

Common Variant Near HEY2 Has a Protective Effect on Ventricular Fibrillation Occurrence in Brugada Syndrome by Regulating the Repolarization Current.

Nakano Y, Ochi H, Onohara Y, Toshishige M, Tokuyama T, Matsumura H, Kawazoe H, Tomomori S, Sairaku A, Watanabe Y, Ikenaga H, Motoda C, Suenari K, Hayashida Y, Miki D, Oda N, Kishimoto S, Oda N, Yoshida Y, Tashiro S, Chayama K, Kihara Y.

Circ Arrhythm Electrophysiol. 2016 Jan;9(1):e003436. doi: 10.1161/CIRCEP.115.003436.

PMID:
26729854
47.

Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report.

Tsuge M, Hiramatsu A, Shinohara F, Nakano N, Nakamura Y, Hatooka M, Morio K, Morio R, Kan H, Fujino H, Uchida T, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Ono A, Nagaoki Y, Miki D, Kawaoka T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Ochi H, Nelson Hayes C, Chayama K.

Hepatol Res. 2016 Aug;46(9):944-8. doi: 10.1111/hepr.12629. Epub 2016 Jan 30.

PMID:
26613201
48.

Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.

Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, Morio K, Kan H, Fujino H, Kobayashi T, Fukuhara T, Masaki K, Ono A, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Kawakami Y, Ochi H, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol Hepatol. 2016 May;31(5):1009-15. doi: 10.1111/jgh.13236.

PMID:
26584407
49.

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.

Kan H, Hiraga N, Imamura M, Hayes CN, Uchida T, Miyaki E, Tsuge M, Abe H, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antivir Ther. 2016;21(4):307-15. doi: 10.3851/IMP3009. Epub 2015 Nov 12.

PMID:
26562322
50.

Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.

Murakami E, Tsuge M, Hiraga N, Kan H, Uchida T, Masaki K, Nakahara T, Ono A, Miki D, Kawaoka T, Abe H, Imamura M, Aikata H, Ochi H, Hayes CN, Akita T, Tanaka J, Chayama K.

J Infect. 2016 Jan;72(1):91-102. doi: 10.1016/j.jinf.2015.09.038. Epub 2015 Oct 26.

PMID:
26515673

Supplemental Content

Support Center